Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd (LALPATHLAB) is scheduled to report results on 4 Nov 2026. Dr. Lal PathLabs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹798 crore and net profit of ₹170 crore. The stock last traded at ₹2,000, a market capitalisation of ₹33,570 crore, on a P/E of 59.7. Over the past 52 weeks the stock has ranged between ₹1,272 and ₹2,039. Figures are as of 6 Oct 2026 and are not real time.
Dr. Lal PathLabs Ltd share price and key metrics
- Current price
- ₹2,000
- Market cap
- ₹33,570 cr
- Stock P/E
- 59.7
- Book value
- ₹150
- ROE
- 22.3%
- ROCE
- 28.0%
- Dividend yield
- 0.70%
- 52w high / low
- 2039/1272
Metrics as of 6 Oct 2026. Not real time.
Track Dr. Lal PathLabs Ltd
Cruxal reads every Dr. Lal PathLabs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Dr. Lal PathLabs Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 12%
- 3 Years
- 11%
- TTM
- 14%
- 10 Years
- 15%
- 5 Years
- 12%
- 3 Years
- 30%
- TTM
- 10%
- 10 Years
- 14%
- 5 Years
- 1%
- 3 Years
- 17%
- 1 Year
- 24%
- 10 Years
- 22%
- 5 Years
- 21%
- 3 Years
- 22%
- Last Year
- 22%
Dr. Lal PathLabs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹798 cr, up 19.1% from ₹670 cr a year earlier. Net profit was ₹170 cr, up 26.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 |
| Expenses | 458 | 443 | 434 | 478 | 506 | 480 | 516 | 550 |
| Operating profit | 202 | 154 | 169 | 192 | 224 | 179 | 187 | 248 |
| OPM % | 31% | 26% | 28% | 29% | 31% | 27% | 27% | 31% |
| Other income | 22 | 25 | 26 | 28 | 25 | -6 | 24 | 32 |
| Interest | 6 | 5 | 5 | 5 | 5 | 7 | 6 | 6 |
| Depreciation | 35 | 36 | 36 | 35 | 40 | 42 | 45 | 44 |
| Profit before tax | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 |
| Tax % | 29% | 29% | -1% | 26% | 25% | 26% | 17% | 25% |
| Net profit | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 170 |
| EPS (₹) | 7.73 | 5.78 | 9.26 | 7.90 | 8.99 | 5.40 | 7.84 | 10.11 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Dr. Lal PathLabs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 912 | 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 | 2,891 |
| Operating profit | 238 | 264 | 294 | 344 | 436 | 561 | 490 | 609 | 698 | 783 | 838 |
| OPM % | 26% | 25% | 24% | 26% | 28% | 27% | 24% | 27% | 28% | 28% | 29% |
| Net profit | 156 | 172 | 200 | 228 | 296 | 350 | 241 | 362 | 492 | 510 | 546 |
| EPS (₹) | 9.31 | 10.24 | 11.95 | 13.55 | 17.49 | 20.69 | 14.33 | 21.42 | 29.14 | 30.13 | 32.34 |
TTM is the trailing twelve months to the most recent quarter.
Dr. Lal PathLabs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 168 |
| Reserves | 512 | 705 | 862 | 949 | 1,162 | 1,418 | 1,583 | 1,766 | 2,089 | 2,341 |
| Borrowings | 0 | 0 | 0 | 0 | 150 | 533 | 420 | 247 | 157 | 199 |
| Other liabilities | 95 | 128 | 145 | 341 | 265 | 309 | 297 | 357 | 383 | 433 |
| Total liabilities | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,343 | 2,383 | 2,454 | 2,713 | 3,140 |
| Fixed assets | 152 | 208 | 209 | 413 | 447 | 1,369 | 1,305 | 1,228 | 1,168 | 1,256 |
| CWIP | 18 | 10 | 3 | 11 | 10 | 15 | 5 | 6 | 3 | 7 |
| Investments | 106 | 145 | 185 | 164 | 59 | 65 | 150 | 114 | 327 | 423 |
| Other assets | 414 | 554 | 694 | 786 | 1,144 | 893 | 923 | 1,107 | 1,215 | 1,454 |
| Total assets | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,343 | 2,383 | 2,454 | 2,713 | 3,140 |
As reported by the company. Total assets equal total liabilities by construction.
Dr. Lal PathLabs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 171 | 197 | 219 | 284 | 398 | 447 | 456 | 535 | 569 | 636 |
| Cash from investing | -137 | -172 | -100 | -26 | -212 | -449 | -287 | -24 | -303 | -422 |
| Cash from financing | -32 | 13 | -55 | -190 | -139 | 136 | -283 | -414 | -334 | -264 |
| Net cash flow | 2 | 37 | 64 | 67 | 48 | 134 | -114 | 97 | -68 | -50 |
| Free cash flow | 120 | 125 | 177 | 205 | 339 | -28 | 412 | 479 | 516 | 463 |
| CFO / operating profit | 102% | 110% | 110% | 110% | 115% | 103% | 115% | 110% | 105% | 104% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Dr. Lal PathLabs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 43% | 38% | 35% | 32% | 33% | 29% | 18% | 25% | 29% | 28% |
| Debtor days | 17 | 14 | 16 | 14 | 15 | 15 | 13 | 13 | 13 | 15 |
| Inventory days | 33 | 44 | 40 | 70 | 39 | 38 | 28 | 30 | 27 | 30 |
| Days payable | 97 | 106 | 111 | 144 | 132 | 107 | 127 | 151 | 127 | 123 |
| Cash conversion cycle | -47 | -47 | -55 | -60 | -78 | -54 | -87 | -108 | -86 | -79 |
| Working capital days | 19 | 17 | 0 | -19 | -26 | -54 | -56 | -46 | -30 | -29 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Dr. Lal PathLabs Ltd shareholding pattern
Promoters held 53.19% at Jun 2026, down from 53.79% at Jun 2025. FIIs 17.35% and DIIs 21.59%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 53.92% | 53.91% | 53.91% | 53.79% | 53.21% | 53.21% | 53.21% | 53.19% |
| FIIs | 26.82% | 26.82% | 23.90% | 21.69% | 21.86% | 20.29% | 17.18% | 17.35% |
| DIIs | 12.60% | 12.88% | 15.79% | 17.62% | 18.22% | 19.20% | 21.37% | 21.59% |
| Government | 0.29% | 0.29% | 0.29% | 0.29% | 0.27% | 0.01% | 0.01% | 0.01% |
| Public | 6.02% | 5.82% | 5.84% | 6.22% | 6.07% | 6.94% | 7.88% | 7.48% |
| No. of shareholders | 1,16,606 | 1,16,236 | 1,15,699 | 1,18,656 | 1,12,703 | 1,16,167 | 1,14,527 | 1,11,037 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Dr. Lal PathLabs Ltd’s next results date?
Dr. Lal PathLabs Ltd’s next results are scheduled for 4 Nov 2026.
- Earnings resultsConsider and approve un-audited standalone and consolidated financial results for the quarter and half year ending September 30, 2026
- Merger acquisitionAcquisition of 70% stake in SN Genelab Private Limited
See the full results calendar for every Indian company reporting in the next 30 days.
Dr. Lal PathLabs Ltd corporate filings
- AttachedCompany Updatelow impact
- Dr. Lal PathLabs Intimates Regulatory Filing Under Regulation 30Company Updatelow impact
Cruxal's analysis: The company has submitted a regulatory disclosure on October 8, 2026. No financial or…
Read the full analysis - Dr. Lal PathLabs completes acquisition of stake in SN Genelab Private Limited on October 01, 2026Company Updatemedium impact
Cruxal's analysis: Dr. Lal PathLabs has finalized its acquisition of a stake in SN Genelab Private Limited…
Read the full analysis - Dr. Lal PathLabs completes acquisition of 80% stake in Sunshine Healthcare Limited, GhanaCompany Updatemedium impact
Cruxal's analysis: Dr. Lal PathLabs Limited has officially completed the acquisition of an 80% equity stake…
Read the full analysis - AttachedInsider Trading / SASTlow impact
- Dr. Lal PathLabs schedules Board Meeting for November 04, 2026, to approve Q2 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Dr. Lal PathLabs Limited has formally intimated the stock exchanges regarding a Board of…
Read the full analysis - Dr. Lal PathLabs to acquire 70% stake in SN Genelab for up to 199.5 crore to bolster genomics portfolioCompany Updatehigh impact
Cruxal's analysis: Dr. Lal PathLabs Limited has announced the acquisition of a 70% controlling stake in SN…
Read the full analysis - Dr. Lal PathLabs Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Dr. Lal PathLabs has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Dr. Lal PathLabs completes 30% strategic stake acquisition in Neuome TechnologiesCompany Updatemedium impact
Cruxal's analysis: Dr. Lal PathLabs Limited has officially completed the subscription of a 30% equity stake…
Read the full analysis - Dr. Lal PathLabs Ltd incorporates new step-down subsidiaryCompany Updatelow impact
Cruxal's analysis: Dr. Lal PathLabs Ltd has announced the incorporation of a new step-down subsidiary…
Read the full analysis - Dr. Lal PathLabs Ltd announces allotment of equity shares under ESOP schemeCompany Updatelow impact
Cruxal's analysis: Dr. Lal PathLabs has completed the allotment of equity shares pursuant to the exercise of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.